The early detection of relapse (recurrence) is currently based on the presence of clinical symptoms, blood biomarkers with various sensitivity and specificity (e.g., carcinoembryonic antigen (CEA) for colorectal carcinoma (CRC), prostate-specific antigen (PSA) for prostate cancer, and cancer antigen 15-3 (CA 15-3) for breast cancer), and radiologic evidence of the disease [85]. The gene discussed is PSAT1; the disease is prostate carcinoma.